New bis(pyridyl)methane derivatives from 4-hydroxy-2-pyridones: Synthesis and antitumoral activity

European Journal of Medicinal Chemistry

Volumn 38, Issue 1, 2003, Pages 37-47

  Cocco, Maria Teresa ^a   Congiu, Cenzo ^a   Onnis, Valentina ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Antitumoral activity; Bis(pyridyl)methanes; Pyridones

Indexed keywords

1 [BIS(3 CYANO 4 HYDROXY 2 MORPHOLINO 1,6 DIHYDRO 6 OXOPYRIDIN 5 YL)METHYL] 2,6 DICHLOROBENZENE; 1 [BIS(3 CYANO 4 HYDROXY 2 MORPHOLINO 1,6 DIHYDRO 6 OXOPYRIDIN 5 YL)METHYL] 4 FLUOROBENZENE; 1 [BIS(3 CYANO 4 HYDROXY 2 PYRROLIDINO 1,6 DIHYDRO 6 OXOPYRIDIN 5 YL)METHYL] 2,6 DICHLOROBENZENE; 1 [BIS(3 CYANO 4 HYDROXY 2 PYRROLIDINO 1,6 DIHYDRO 6 OXOPYRIDIN 5 YL)METHYL] 4 FLUOROBENZENE; 1 [BIS[2 ETHOXY (3 ETHOXYCARBONYL) 4 HYDROXY 1,6 DIHYDRO 6 OXOPYRIDIN 5 YL]METHYL] 2,6 DICHLOROBENZENE; 1 [BIS[2 ETHOXY (3 ETHOXYCARBONYL) 4 HYDROXY 1,6 DIHYDRO 6 OXOPYRIDIN 5 YL]METHYL] 4 FLUOROBENZENE; 1 [BIS[2 ETHOXY 3 (ETHOXYCARBONYL) 4 HYDROXY 1,6 DIHYDRO 6 OXOPYRIDIN 5 YL]METHYL] 4 METHYLBENZENE; 1 [BIS[3 (ETHOXYCARBONYL) 4 HYDROXY 2 (4 METHYLPIPERAZINO) 1,6 DIHYDRO 6 OXOPYRIDIN 5 YL]METHYL] 2,6 DICHLOROBENZENE; 1 [BIS[3 (ETHOXYCARBONYL) 4 HYDROXY 2 (4 PHENYLPIPERAZINO) 1,6 DIHYDRO 6 OXOPYRIDIN 5 YL]METHYL] 4 FLUOROBENZENE; 1 [BIS[3 (ETHOXYCARBONYL) 4 HYDROXY 2 MORPHOLINO 1,6 DIHYDRO 6 OXOPYRIDIN 5 YL]METHYL] 2 CHLOROBENZENE; 1 [BIS[3 (ETHOXYCARBONYL) 4 HYDROXY 2 MORPHOLINO 1,6 DIHYDRO 6 OXOPYRIDIN 5 YL]METHYL] 2,4 DICHLOROBENZENE; 1 [BIS[3 (ETHOXYCARBONYL) 4 HYDROXY 2 MORPHOLINO 1,6 DIHYDRO 6 OXOPYRIDIN 5 YL]METHYL] 4 CHLOROBENZENE; 1 [BIS[3 (ETHOXYCARBONYL) 4 HYDROXY 2 MORPHOLINO 1,6 DIHYDRO 6 OXOPYRIDIN 5 YL]METHYL] 4 FLUOROBENZENE; 1 [BIS[3 (ETHOXYCARBONYL) 4 HYDROXY 2 MORPHOLINO 1,6 DIHYDRO 6 OXOPYRIDIN 5 YL]METHYL] 4 METHYLBENZENE; 1 [BIS[3 (ETHOXYCARBONYL) 4 HYDROXY 2 PYRROLIDINO 1,6 DIHYDRO 6 OXOPYRIDIN 5 YL]METHYL] 2,6 DICHLOROBENZENE; 1 [BIS[3 (ETHOXYCARBONYL) 4 HYDROXY 2 PYRROLIDINO 1,6 DIHYDRO 6 OXOPYRIDIN 5 YL]METHYL] 4 CHLORO 2 NITROBENZENE; 1 [BIS[3 CYANO 4 HYDROXY 2 (4 METHYLPIPERAZINO) 1,6 DIHYDRO 6 OXOPYRIDIN 5 YL]METHYL] 2,6 DICHLOROBENZENE; 1 [BIS[3 CYANO 4 HYDROXY 2 (4 METHYLPIPERAZINO) 1,6 DIHYDRO 6 OXOPYRIDIN 5 YL]METHYL] 4 FLUOROBENZENE; 1 [BIS[3 CYANO 4 HYDROXY 2 [4 (ETHOXYCARBONYL)PIPERAZINO] 1,6 DIHYDRO 6 OXOPYRIDIN 5 YL]METHYL] 2,6 DICHLOROBENZENE; 1 [BIS[3 CYANO 4 HYDROXY 2 [4 (ETHOXYCARBONYL)PIPERAZINO] 1,6 DIHYDRO 6 OXOPYRIDIN 5 YL]METHYL] 4 FLUOROBENZENE; 2 [BIS[2 ETHOXY (3 ETHOXYCARBONYL) 4 HYDROXY 1,6 DIHYDRO 6 OXOPYRIDIN 5 YL]METHYL]THIOPHENE; ALDEHYDE; ANTINEOPLASTIC AGENT; BIS[3 (ETHOXYCARBONYL) 4 HYDROXY 2 (4 PHENYLPIPERAZINO) 1,6 DIHYDRO 6 OXOPYRIDIN 5 YL]METHYLBENZENE; BIS[3 (ETHOXYCARBONYL) 4 HYDROXY 2 MORPHOLINO 1,6 DIHYDRO 6 OXOPYRIDIN 5 YL]METHYLBENZENE; BIS[3 (ETHOXYCARBONYL) 4 HYDROXY 2 PYRROLIDINO 1,6 DIHYDRO 6 OXOPYRIDIN 5 YL]METHYLBENZENE; BIS[3 CYANO 4 HYDROXY 2 [4 (ETHOXYCARBONYL)PIPERAZINO] 1,6 DIHYDRO 6 OXOPYRIDIN 5 YL]METHYLBENZENE; PYRIDINE DERIVATIVE; PYRIDONE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; METHANE; MODELS, CHEMICAL; MOLECULAR STRUCTURE; PYRIDINES; PYRIDONES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037368423     PISSN: 02235234     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0223-5234(02)00002-8     Document Type: Article

References (12)

1. Cocco M.T., Congiu C., Onnis V. Eur. J. Med. Chem. 37:2000;267-272.
2. Plowman J., Dykes D.J., Hollingshead M., Simpson-Herren L., Alley M.C. Human tumour xenograft models in NCI drug development. Teicher B. Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval. 1997;101-125 Humana Press, Totowa, NJ.
3. Hollingshead M., Alley M.C., Camelier R.F., Abbott B.J., Mayo J.G., Malspeis L., Grever M.R. Life Sci. 57:1995;131-141.
4. Grever M.R., Schepartz S.A., Chabner B.A. Semin. Oncol. 19:1992;622-638.
5. Boyd M.R., Paul K.D. Drug Dev. Res. 34:1995;91.
6. Skehan P., Storeng R., Scudiero D., et al. J. Natl. Cancer Inst. 82:1990;1107.
7. Boyd M.R. Princ. Pract. Oncol. 3:1989;1.
8. Cocco M.T., Congiu C., Maccioni A., Plumitallo A., Schivo M.L., Palmieri G. Farmaco. 43:1988;103-112.
9. Cocco M.T., Congiu C., Maccioni A., Schivo M.L., De Logu A., Palmieri G. Farmaco. 43:1988;951-960.
10. Bonsignore L., Cocco M.T., Loy G., Onnis V. J. Heterocycl. Chem. 29:1992;237-239.
11. Gray G.D., Wickstrom E. Biotechniques. 21:1996;780-782.
12. Monks A., Scudiero D., Skehan P., Shoemaker R., Paull K., Vistica D., et al. J. Natl. Cancer Inst. 83:1991;757.